• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Accuray Incorporated

    11/26/24 4:01:44 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care
    Get the next $ARAY alert in real time by email
    S-8 1 form_s-8_11.26.24.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on November 26, 2024

    Registration No. 333-______

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    ACCURAY INCORPORATED

    (Exact name of registrant as specified in its charter)

     

    Delaware
    (State or Other Jurisdiction of
    Incorporation or Organization)

     

    20-8370041

    (I.R.S. Employer
    Identification Number)


    ———————————————

     

    1240 Deming Way

    Madison, Wisconsin 53717

    (Address of Principal Executive Offices including Zip Code)

     

     

    Accuray Incorporated Amended and Restated 2016 Equity Incentive Plan (the “Employee Plan”)

    Accuray Incorporated Amended and Restated 2007 Employee Stock Purchase Plan

    Accuray Incorporated Stand-Alone Inducement Restricted Stock Unit Agreement

    (Full Title of the Plan)

     

     

    Suzanne Winter
    President and Chief Executive Officer
    Accuray Incorporated
    1240 Deming Way

    Madison, WI 53717
    (608) 824-2800

    Copy to:
    Katharine A. Martin

    Lisa L. Stimmell

    Wilson Sonsini Goodrich & Rosati, P.C.

    650 Page Mill Road

    Palo Alto, CA 94304

    (650) 493-9300

    (Name and Address, Including Zip Code, and Telephone Number,
    Including Area Code, of Agent for Service)

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer  Accelerated filer 

     

    Non-accelerated filer  Smaller reporting company 

     

     

     


     

    Emerging Growth Company 

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. 

     

     

     

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference

    The following documents, which were filed with the Securities and Exchange Commission (the “Commission”), are incorporated herein by reference (excluding any portions of such documents that have been “furnished” but not “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)):

    (a)
    The Registrant’s Annual Report on Form 10-K for the fiscal year ended June 30, 2024, filed with the Commission on September 19, 2024 (File No. 001-33301) (including portions incorporated by reference to the Registrant’s proxy statement on Schedule 14A);

     

    (b)
    The Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2024 filed with the Commission (File No. 001-33301) on November 6, 2024;

     

    (c)
    The Registrant’s Current Reports on Form 8-K filed with the Commission (File No. 001-33301) on September 3, 2024, September 16, 2024, October 15, 2024, and November 25, 2024 (other than the portions of these documents not deemed to be filed); and

     

    (d)
    The description of the Common Stock contained in the Registrant’s Registration Statement on Form 8-A filed with the Commission on February 7, 2007 (File No. 001-33301), including any subsequently filed amendments and reports updating that description.

     

    All documents subsequently filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or deregistering all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in this Registration Statement, or in any subsequently filed document which also is or is deemed to be incorporated by reference in this Registration Statement, modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to be a part of this Registration Statement. Information contained in a Current Report on Form 8-K furnished to the Commission will not be incorporated by reference into this Registration Statement.

    Item 4. Description of Securities

    The Common Stock being registered hereunder has been registered pursuant to Section 12 of the Exchange Act.

    Item 5. Interests of Named Experts and Counsel

    Not applicable.

    Item 6. Indemnification of Directors and Officers

     

     


     

    Section 145 of the General Corporation Law of the State of Delaware (the “DGCL”) authorizes a corporation’s board of directors to grant, and authorizes a court to award, indemnity to officers, directors and other corporate agents under certain circumstances.

    As permitted by Section 102(b)(7) of the DGCL, the Registrant’s amended and restated certificate of incorporation contains provisions that limit the liability of its directors for monetary damages to the fullest extent permitted by Delaware law. Consequently, the Registrant’s directors will not be personally liable to the Registrant or its stockholders for monetary damages for any breach of fiduciary duties as directors, except liability for the following:

    •
    any breach of the director’s duty of loyalty to the Registrant or to its stockholders;
    •
    acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;
    •
    unlawful payment of dividends or unlawful stock repurchases or redemptions; and
    •
    any transaction from which the director derived an improper personal benefit.

    The Registrant’s certificate of incorporation provides that it may indemnify to the fullest extent permitted by law any person made or threatened to be made a party to an action or proceeding, whether criminal, civil, administrative or investigative, by reason of the fact that he, his testator or intestate is or was a director, officer, employee or agent of the Registrant or any predecessor of the Registrant, or serves or served at any other enterprise as a director, officer, employee or agent at the request of the Registrant or any predecessor to the Registrant.

    If Delaware law is amended to authorize corporate action further eliminating or limiting the personal liability of a director, then the liability of the Registrant’s directors will be eliminated or limited to the fullest extent permitted by Delaware law, as so amended. The Registrant’s amended and restated certificate of incorporation does not eliminate a director’s duty of care and, in appropriate circumstances, equitable remedies, such as injunctive or other forms of non-monetary relief, remain available under Delaware law. This provision also does not affect a director’s responsibilities under any other laws, such as the federal securities laws or other state or federal laws.

    The Registrant’s amended and restated bylaws provide that the Registrant shall indemnify and hold harmless, to the fullest extent permitted by the DGCL as it presently exists or may hereafter be amended, any director or officer of the Registrant who was or is made or is threatened to be made a party or is otherwise involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative by reason of the fact that he or she, or a person for whom he or she is the legal representative, is or was a director, officer, employee or agent of the Registrant or is or was serving at the request of the Registrant as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust, enterprise or non-profit entity, including service with respect to employee benefit plans, against all liability and loss suffered and expenses reasonably incurred by such person in connection with any such action, suit or proceeding.

    Further, the Registrant has entered into indemnification agreements with each of its current directors and officers. These agreements provide for the indemnification of the Registrant’s directors and officers for all reasonable expenses and liabilities incurred in connection with any action or proceeding brought against them by reason of the fact that they are or were the Registrant’s agents. The Registrant also maintains directors’ and officers’ liability insurance.

    Item 7. Exemption from Registration Claimed

    Not applicable.

    Item 8. Exhibits

     

     

     

     

     

     

     

    Exhibit No.

    Exhibit Descriptions

     

     

     

     

     

     

     

     


     

    4.1(1)

    Form of Common Stock Certificate.

     

     

     

     

     

    5.1(2)

    Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation.

     

     

     

     

     

    23.1(2)

    Consent of Wilson Sonsini Goodrich & Rosati, Professional Corporation (included in Exhibit 5.1).

     

     

     

     

     

    23.2(2)

    Consent of Grant Thornton LLP, independent registered public accounting firm.

     

     

     

     

     

    24.1(2)

    Power of Attorney (contained on signature page hereto).

     

     

     

     

     

    99.1(3)

    Accuray Incorporated Amended and Restated 2016 Equity Incentive Plan and forms of award agreements thereunder.

     

     

     

     

     

    99.2(4)

    Accuray Incorporated Amended and Restated 2007 Employee Stock Purchase Plan.

     

     

     

     

     

    99.3(2)

    Form of Accuray Incorporated Stand-Alone Inducement Restricted Stock Unit Agreement

     

     

     

     

     

    107.1(2)

    Filing Fee Table

     

     

     

     

     

     

    (1)
    Incorporated by reference to Exhibit 4.3 filed with the Registrant’s Registration Statement on Form S-1/A (Registration No. 333-138622), filed with the Commission on February 5, 2007.
    (2)
    Filed herewith.
    (3)
    Incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on November 25, 2024 (No. 001-33301).
    (4)
    Incorporated herein by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed with the Commission on November 25, 2024 (No. 001-33301).

     

    Item 9. Undertakings

    (a) The undersigned Registrant hereby undertakes:

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

    (ii) To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee” table in the effective Registration Statement.

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the Registration Statement;

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by

     

     


     

    the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Madison, State of Wisconsin, on the 26th day of November, 2024.

     

    Accuray Incorporated

     

     

     

     

    By:

    /s/ Suzanne Winter

    Suzanne Winter
    President and Chief Executive Officer

     

     

     

     

     

     

     

     

     


     

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Suzanne Winter and Ali Pervaiz and each of them acting individually, as his or her true and lawful attorneys-in-fact and agents, with full power of each to act alone, with full powers of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this registration statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, with full power of each to act alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his, her or their substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

     

     

     

     

     

     

    Signature

     

     

     

     

    Title

     

     

     

     

    Date

     

     

     

     

     

    /s/ Suzanne Winter

    Suzanne Winter

    President and Chief Executive Officer and Director (principal executive officer)

    November 26, 2024

     

     

     

    /s/Ali Pervaiz

    Ali Pervaiz

    Chief Financial Officer (principal financial officer)

    November 26, 2024

     

     

     

     

    Joseph E. Whitters

    Chairperson of the Board and Director

     

     

     

     

     

    Robert C. Kill

     

    Director

     

     

     

     

     

     

    /s/ Anne B. Le Grand

    Anne B. Le Grand

    Director

    November 26, 2024

     

     

    /s/ James M. Hindman

    James M. Hindman

     

     

    Director

     

    November 26, 2024

     

    /s/ Byron C. Scott

    Byron C. Scott

     

    Director

    November 26, 2024

     

     

    /s/ Beverly A. Huss

    Beverly A. Huss

     

     

    Director

     

    November 26, 2024

     

    /s/ Mika Nishimura

    Mika Nishimura

     

     

    Director

     

    November 26, 2024

     

     

     


    Get the next $ARAY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARAY

    DatePrice TargetRatingAnalyst
    2/13/2024$9.00Buy
    ROTH MKM
    6/23/2022$7.50Buy
    B. Riley Securities
    12/22/2021$7.50Buy
    Loop Capital
    More analyst ratings

    $ARAY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Accuray to Participate in the Jefferies Global Healthcare Conference 2025

      MADISON, Wis., May 29, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today its participation in the Jefferies Global Healthcare Conference 2025. The management team is scheduled to participate in a fireside chat on Wednesday, June 4th, 2025, at 5:30pm EDT/2:30pm PDT. A live webcast of the call will also be available from the Investor Relations section of the company's website at investors.accuray.com. A webcast replay can be accessed on the website and will remain available for 90 days. About AccurayAccuray is committed to expanding the powerful potential o

      5/29/25 7:30:00 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Accuray Showcases New Long-Term Data¹ on Benefits of 5 Session Radiotherapy Treatment for Men with Prostate Cancer at ESTRO 2025

      More than 40 Clinical Studies Using Accuray Technology Presented at ESTRO 2025; Company Highlights Innovation and Educational Symposia MADISON, Wis., May 7, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that new data presented at the European Society for Radiotherapy and Oncology (ESTRO) meeting reinforces the benefits of the company's CyberKnife® System in the treatment of prostate cancer at multiple stages of the cancer journey. The studies, shared at the annual congress held in Vienna, Austria, indicate the system's accuracy and precision enable treatment of high-risk disease, as well as recurrent prostate cancer following prostatectomy, with stereotactic body r

      5/7/25 7:35:00 AM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Accuray Announces First SRS/SBRT Patient Treatments in Austria With the CyberKnife® System

      Medical Team's Use of Accuray CyberComm™ Reduced Commissioning Time by Approximately 50 Percent*, Enabling Them to Initiate Patient Treatments Sooner MADISON, Wis., May 5, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that the CyberKnife® Center Salzburg is the first in Austria to treat patients with the CyberKnife® System, expanding access to stereotactic radiosurgery (SRS) and ultra-hypofractionated stereotactic body radiation therapy (SBRT), treatment processes necessitating an extremely high degree of precision and accuracy. The CyberKnife Center Salzburg's team used the Accuray CyberComm™ technology to commission their system, the latest-generation CyberKnife S

      5/5/25 4:10:00 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care

    $ARAY
    SEC Filings

    See more
    • SEC Form SD filed by Accuray Incorporated

      SD - ACCURAY INC (0001138723) (Filer)

      5/30/25 4:01:08 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Accuray Incorporated

      10-Q - ACCURAY INC (0001138723) (Filer)

      5/2/25 4:05:24 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Accuray Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ACCURAY INC (0001138723) (Filer)

      4/30/25 4:10:13 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care

    $ARAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Accuray with a new price target

      ROTH MKM initiated coverage of Accuray with a rating of Buy and set a new price target of $9.00

      2/13/24 6:29:42 AM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • B. Riley Securities initiated coverage on Accuray with a new price target

      B. Riley Securities initiated coverage of Accuray with a rating of Buy and set a new price target of $7.50

      6/23/22 7:25:39 AM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Loop Capital initiated coverage on Accuray with a new price target

      Loop Capital initiated coverage of Accuray with a rating of Buy and set a new price target of $7.50

      12/22/21 4:56:14 AM ET
      $ARAY
      Medical/Dental Instruments
      Health Care

    $ARAY
    Financials

    Live finance-specific insights

    See more
    • Accuray Reports Fiscal 2025 Third Quarter Financial Results

      MADISON, Wis., April 30, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the third quarter ended March 31, 2025. Key Fiscal Third Quarter Highlights: Total net revenue was $113.2 million, an increase of 12 percent year-over-yearNet loss was $1.3 million compared to a net loss of $6.3 million in the prior year periodAdjusted EBITDA was $6.0 million compared to $1.1 million in the prior year period"We achieved a strong third quarter and I am proud of the resiliency of the entire team and their focus on driving actions to mitigate the

      4/30/25 4:05:00 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Accuray to Report Third Quarter Fiscal 2025 Financial Results on April 30, 2025

      MADISON, Wis., April 16, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the third quarter of fiscal year 2025, ended March 31, 2025, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on April 30, 2025. The conference call dial-in numbers are 1-833-316-0563 (USA) or 1-412-317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is 1-877-344-7529 (USA) or 1-412-317-0088 (internationa

      4/16/25 4:05:00 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Accuray Reports Strong Fiscal 2025 Second Quarter Financial Results & Raises Guidance

      MADISON, Wis., Feb. 5, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the second quarter ended December 31, 2024. Key Fiscal Q2 Highlights: Strong second quarter and first half results; raising fiscal year 2025 guidanceTotal net revenue was $116.2 million, an increase of 8 percent year-over-yearNet income was $2.5 million compared to a net loss of $9.6 million in the prior year periodAdjusted EBITDA was $9.6 million compared to $2.0 million in the prior year period"Our strong Q2 performance reflects outstanding execution of our str

      2/5/25 4:05:00 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care

    $ARAY
    Leadership Updates

    Live Leadership Updates

    See more
    • Leonel Peralta to Join Accuray as Chief Operations Officer

      MADISON, Wis., Jan. 21, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that Leonel Peralta is joining the company as Senior Vice President, Chief Operations Officer, effective February 3, 2025. Mr. Peralta will be responsible for leading worldwide manufacturing operations including driving alignment of operations with corporate business goals, maximizing supply chain profitability and efficiency, and ensuring processes support best-in-class customer service. He will report to Accuray President and Chief Executive Officer Suzanne Winter. Mr. Peralta has

      1/21/25 9:15:00 AM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Accuray Appoints Michael Murphy as VP, Corporate Controller

      MADISON, Wis., Oct. 21, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that Michael Murphy, CPA has joined the company as Vice President, Corporate Controller. Mr. Murphy will be responsible for leading the global accounting function including corporate tax, regulatory reporting, accounting policies, and risk management, along with associated budgetary and administrative operations. He will report to Accuray Senior Vice President & Chief Financial Officer Ali Pervaiz. The company also expects to appoint Mr. Murphy to the position of principal accounting officer following the filing of the company's quarterly report on Form 10-Q for the period ended September 30, 2024

      10/21/24 4:05:00 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Robert C. Kill Joins Accuray Board of Directors

      SUNNYVALE, Calif., Feb. 1, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today the appointment of Robert C. Kill to the company's Board of Directors, effective as of January 30, 2023. Mr. Kill is a skilled healthcare executive with more than 30 years' experience transforming various healthcare-related companies. In his most recent executive position as CEO of Parata Systems, Mr. Kill grew company revenue over 5X during his tenure before it sold last year for more than $1.5 billion. Before Parata, Mr. Kill was affiliated with two private equity funds, Frazie

      2/1/23 4:10:00 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care

    $ARAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Accuray Incorporated

      SC 13G/A - ACCURAY INC (0001138723) (Subject)

      9/6/24 9:00:07 AM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Accuray Incorporated

      SC 13G - ACCURAY INC (0001138723) (Subject)

      2/13/24 4:56:01 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Accuray Incorporated (Amendment)

      SC 13G/A - ACCURAY INC (0001138723) (Subject)

      2/13/24 11:19:22 AM ET
      $ARAY
      Medical/Dental Instruments
      Health Care

    $ARAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by SVP, Chief Operations Officer Peralta Leonel

      4 - ACCURAY INC (0001138723) (Issuer)

      3/3/25 5:41:56 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • SEC Form 3 filed by new insider Peralta Leonel

      3 - ACCURAY INC (0001138723) (Issuer)

      2/13/25 4:10:11 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • SVP Chief Financial Officer Pervaiz Ali covered exercise/tax liability with 2,013 shares, decreasing direct ownership by 0.55% to 362,231 units (SEC Form 4)

      4 - ACCURAY INC (0001138723) (Issuer)

      1/2/25 5:32:36 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care

    $ARAY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Whitters Joseph E bought $156,045 worth of shares (100,000 units at $1.56), increasing direct ownership by 22% to 561,053 units (SEC Form 4)

      4 - ACCURAY INC (0001138723) (Issuer)

      5/30/24 4:10:11 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care